MARKETS / NASDAQ / PAVM
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

PAVmed Inc. PAVM

11 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$71,000
▼ 97.6% vs FY2024
EPS · FY25
$-5.63
Dividend / sh · FY25
Payout · FY25
ROE · FY25
2.5%
Net margin · FY25
564.8%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 71,000.00
Revenue, FY2025 · full 11-year series below
Revenue Net income
0.00080.00160.00240.00320.00.020152018202120242025
0.00080.00160.00240.00320.00.02016201920222025

565 cents of every revenue dollar became profit this year.

Per share
USD -5.63
Diluted EPS, FY2025
EPS
51015-5.6320152018202120242025
51015-5.632016201920222025

The company pays no cash dividend.

Profitability
2.5%
Return on equity, FY2025
ROE
0.81.62.43.22.5%20152018202120242025
0.81.62.43.22.5%2016201920222025
Operating margin-30712.7%
Net margin564.8%
Return on assets1.2%

Each USD of equity produced 3 cents of profit this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−42.7%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.00B
Shares outstanding, FY2025
0.010.0020152018202120242025
0.010.002016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 38.8M
total assets, end of FY2025
Total assetsUSD 38.8M
EquityUSD 34.0M
CashUSD 1.5M
Current ratio0.17×

Equity funds 88% of total assets.

History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
·
EBITDA $B
−0.0
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
·
Income tax $B
0.0
0.0
·
·
·
·
·
·
·
·
·
Net income $B
0.0
0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−5.63
14.90
−9.16
−15.03
−0.65
−0.72
−0.54
−0.81
−0.71
−0.44
−0.16
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
2.5
·
·
−342.3
−158.4
·
·
·
·
−3589.5
−280.3
Shares out B
0.00
0.00
0.01
0.01
0.09
0.06
0.04
0.02
0.01
0.01
0.01

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
34 of 34
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed